06/21/22 8:00 AMNasdaq : EXEL clinical trialExelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal CancerExelixis, Inc. today announced the initiation of STELLAR-303, a phase 3 pivotal trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer that is not microsatellite instability-high or mismatch repair-deficient, who have progressed after or are intolerant to the standard of care therapy.RHEA-AIneutral
06/16/22 12:00 AMNasdaq : EXEL, BINV Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology TherapiesExelixis, Inc. and BioInvent International AB today announced that the companies have...RHEA-AIvery positive
06/07/22 7:30 AMNasdaq : BTTX, MYOV, EXEL managementlow floatBetter Therapeutics Appoints Frank Karbe as Chief Executive OfficerBetter Therapeutics, Inc., a prescription digital therapeutics company developing nutritional cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5 th, 2022.RHEA-AIvery positive
05/31/22 4:05 PMNasdaq : EXEL conferencesExelixis To Webcast Fireside Chats as Part of Investor Conferences in JuneExelixis, Inc. today announced that members of the company’ s management team will participate in fireside chats at the following investor conferences in June:. William Blair 42 nd Annual Growth Stock Conference: Exelixis is scheduled to present at 11:00 a.m. ET/ 10:00 a.m. CT/ 8:00 a.m. PT on Tuesday, June 7, 2022, in Chicago. 2022 Jefferies Healthcare...RHEA-AIneutral
05/26/22 5:00 PMNasdaq : EXEL Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022Exelixis, Inc. today announced detailed results from multiple cohorts of the phase 1 b COSMIC-021 trial of cabozantinib as a monotherapy and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Data from urothelial carcinoma cohorts 3, 4 and 5 and from non-small cell lung cancer cohorts 7 and 20 will be presented...RHEA-AIneutral
05/26/22 5:00 PMNasdaq : EXEL clinical trialExelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022Exelixis, Inc. today announced results from a phase 2, investigator-sponsored trial of cabozantinib in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma. The data will be presented at the 2022 American Society of Clinical Oncology Annual Meeting during Oral Abstract Session: Head and Neck...RHEA-AIneutral
05/10/22 4:05 PMNasdaq : EXEL earningsExelixis Announces First Quarter 2022 Financial Results and Provides Corporate UpdateExelixis, Inc. today reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. “Exelixis had a strong start to 2022 as we continued to gain momentum across all components of our business,” said Michael M. Morrissey,...RHEA-AIvery positive
05/04/22 4:05 PMNasdaq : EXEL conferencesExelixis To Webcast Fireside Chats as Part of Investor Conferences in MayExelixis, Inc. today announced that members of the company’ s management team will participate in fireside chats at the following investor conferences in May:. BofA Securities 2022 Healthcare Conference: Exelixis is scheduled to present at 1:40 p.m. ET/ 10:40 a.m. PT on Wednesday, May 11, 2022 in Las Vegas. 2022 RBC Capital Markets Global Healthcare...RHEA-AIneutral
05/03/22 8:00 AMNasdaq : EXEL Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerExelixis, Inc. today announced that its partner Ipsen received approval from the European Commission for CABOMETYX ® as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.RHEA-AIvery positive
04/26/22 4:05 PMNasdaq : EXEL earningsExelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022Exelixis, Inc. announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 after the markets close. At 5:00 p.m. ET/ 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Founded in 1994, Exelixis, Inc. is a commercially successful,...RHEA-AIneutral